FTSE 100 Live: London stocks shrug off Iran's Hormuz terms as miners lend support

FTSE 100 was up around 51 points to 10,919 as Brent crude rose above $82 per barrel. Precious metals gains lifted Fresnillo, up about 5%, and Endeavour Mining. The move followed reports of Iran-Oman draft terms on Strait of Hormuz shipping restrictions. Investors also awaited US non-farm payrolls.

Original reporting
Published Aug 7, 2026, 10:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 10:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$AZN
Bullish
low confidence
Mentioned
$AZN · $RTO
Relevance
6/10
AlphAI data visualization · based on proactiveinvestors.co.uk
Decision brief

The 30-second read

$AZNBullishMed
01

Why it matters

Precious-metals miners are bid on gold and silver strength, while energy names benefit from higher Brent. Separately, several single-stock catalysts appear: Goodwin’s sale exploration, Genel’s takeover rejection and DNO’s public offer, and Oxford BioMedica’s guidance cut.

02

Market read

Traders get both macro-driven commodity beta (gold, silver, Brent) and several company-specific catalysts that can drive outsized intraday moves.

03

What to watch

The article notes unusually wide payroll estimate ranges; a surprise could quickly rotate out of commodity beta and into defensives, reversing early winners.

Relevance 6/10Novelty 5/10Timing: pre-market and early London session, ahead of US non-farm payrolls later today

Background

The piece frames early FTSE 100 trading around Iran-Oman Strait of Hormuz draft terms and an upcoming US non-farm payrolls release, with commodities driving sector moves.

Company-level read

Ticker impact

$AZNBullishLow confidence
Context

AstraZeneca recovers some losses as the risk of a merger with Bristol-Myers Squibb is described as having receded.

Expected impact

Potential for continued stabilization, but likely headline-driven and reversible.

Evidence & confidence

The article frames the move as receding merger risk without new deal terms or a definitive resolution, so incremental information is limited.

$RTOBearishLow confidence
Context

Rentokil Initial is down about 1.6% in early trade while the index is supported by miners and oil strength.

Expected impact

Limited conviction without a fresh catalyst.

Evidence & confidence

The article lists the decliner but does not provide a new company event or driver for RTO.

Market effects

Higher Brent and stronger gold/silver are driving cross-asset beta into miners and energy, while oil-sensitive sectors (airlines) lag.

UK large-caps are trading as a proxy for Middle East shipping risk and US payroll expectations.

Hormuz-related shipping terms and US jobs data can move global rates, inflation expectations, and commodity complex pricing.

Counterpoint

The index strength may be temporary if gold and oil gains fade after Hormuz headlines or if payrolls surprise shifts rate expectations.

Key entities

  • Fresnillo PLC

    Precious-metals miner leading FTSE 100 gains on gold and silver price strength.

  • Goodwin PLC

    Engineering group confirming it is exploring a sale of part of its mechanical engineering division.

  • Genel Energy PLC

    Rejecting a £202 million takeover approach while DNO publishes a 69p-a-share cash offer.

  • Oxford BioMedica PLC

    Cutting 2026 guidance with EBITDA expectations slashed by about half.

  • BP PLC

    Up on Brent crude rising back above the low-$80s amid Hormuz-related supply concerns.

Related articles

$AZNMed

AstraZeneca’s HICKORY Trial Fails Primary Endpoint Due to Design Mismatch

AstraZeneca's Phase 3 HICKORY trial for efzimfotase alfa in treating hypophosphatasia (HPP) failed its primary endpoint. The drug showed a 17.05-meter improvement in the 6MWT, but this was not statistically significant. AstraZeneca's Alexion unit noted 45.2% of treated patients achieved a MCID in 6MWT. Analysts attribute the failure to trial design issues, specifically patient population mismatches. Future trials may require better pre-activation phase reviews to avoid similar issues.

$AZNMed

AstraZeneca at ASBMR 2026: rare disease push hinges on new bone drug

AstraZeneca (AZN) presented data on efzimfotase alfa, a potential treatment for hypophosphatasia, at ASBMR 2026. The drug missed the primary endpoint in the HICKORY study but showed improvements in secondary measures. Management maintained peak sales guidance of $3B-$5B and highlighted its potential over the current standard, Strensiq. AZN trades at a P/E of 23.7 with a $246B market cap, and analysts suggest it may be undervalued.

$AZNMed

AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder Despite Missing Key Tria

AstraZeneca (AZN) reported detailed Phase 3 trial results for efzimfotase alfa in treating hypophosphatasia (HPP). Despite missing the primary endpoint, post hoc analysis showed clinically meaningful improvements in key secondary measures. The drug demonstrated continued benefits in an open-label extension and favorable safety profile. AZN shares rose 0.15% premarket.

$AZNMed

AstraZeneca pins bone disease drug’s Phase III failure on high placebo response

AstraZeneca's efzimfotase alfa failed to meet the primary endpoint in a Phase III trial for hypophosphatasia (HPP) due to a high placebo response, according to the company. Despite this, the drug showed some efficacy in post-hoc analyses and secondary endpoints. AstraZeneca plans to continue development, while analysts expect Strensiq's sales to peak at $2bn by 2027.